EP4333845A1 — Iptacopan for the treatment of atypical hemolytic uremic syndrome
Assigned to Novartis AG · Expires 2024-03-13 · 2y expired
What this patent protects
Described herein are methods of treating atypical hemolytic uremic syndrome (aHUS) with the Factor B inhibitor LNP023 (iptacopan) or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.
USPTO Abstract
Described herein are methods of treating atypical hemolytic uremic syndrome (aHUS) with the Factor B inhibitor LNP023 (iptacopan) or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.